The small interfering RNA targeted to apoCIII, plozasiran, significantly reduces triglyceride levels and the incidence of acute pancreatitis in patients with persistent chylomicronaemia, according to results of the Phase 3 PALISADE trial presented at ESC 2024 and published simultaneously in The New England Journal of Medicine.1,2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
